Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Feature
  • Published:

Public biotech in 2016—the numbers

Nature Biotechnology volume 35, pages 623–629 (2017)Cite this article

Subjects

The anticipated decline in the biotech industry's ability to raise capital from public investors and an accompanying slump in biotech markets materialized in 2016, but all is not gloom and doom.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: NASDAQ biotech index over time.
Figure 2
Figure 3: Global biotech industry financing.
Figure 4: Public biotech barometers.
Figure 5

References

  1. Senior, M. Billion-dollar deals end eras of Ariad and Actelion. Nat. Biotechnol. 35, 183–184 (2017).

    Article  CAS  Google Scholar 

  2. Lawrence, S. Biotech's wellspring-a survey of the health of the private sector in 2016. Nat. Biotechnol. 35, 413–420 (2017).

    Article  CAS  Google Scholar 

  3. Morrison, C. Fresh from the biotech pipeline—2016. Nat. Biotechnol. 35, 108–112 (2017).

    Article  CAS  Google Scholar 

  4. Levin, J.M. et al. US immigration order strikes against biotech. Nat. Biotechnol. 35, 204–206 (2017).

    Article  CAS  Google Scholar 

  5. Garber, K. Alnylam terminates revusiran program, stock plunges. Nat. Biotechnol. 34, 1213–1214 (2016).

    Article  CAS  Google Scholar 

  6. Huggett, B. America's drug problem. Nat. Biotechnol. 34, 1231–1241 (2017).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Chris Morrison is a freelance writer based in Yardley, Pennsylvania, USA, and,

    Chris Morrison

  2. Riku Lähteenmäki is a freelance writer working in Turku, Finland.,

    Riku Lähteenmäki

Authors
  1. Chris Morrison
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Riku Lähteenmäki
    View author publications

    You can also search for this author in PubMed Google Scholar

Supplementary information

Supplementary Text and Figures

Supplementary Table 1 (XLS 212 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Morrison, C., Lähteenmäki, R. Public biotech in 2016—the numbers. Nat Biotechnol 35, 623–629 (2017). https://doi.org/10.1038/nbt.3917

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.3917

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research